Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro

Transplantation

Volumn 61, Issue 1, 1996, Pages 140-145

  Chong, Anita S F ^a   Rezai, Katayoun ^a   Gebel, Howard M ^a   Finnegan, Alison ^a   Foster, Preston ^a   Xu, Xiulong ^a   Williams, James W ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREQUINAR; CYCLOSPORIN; INTERLEUKIN 2; LEFLUNOMIDE; MYCOPHENOLIC ACID; RAPAMYCIN; TERIFLUNOMIDE;

ARTICLE; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PYRIMIDINE SYNTHESIS; T LYMPHOCYTE ACTIVATION;

CELL DIVISION; CELLS, CULTURED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; ISOXAZOLES; T-LYMPHOCYTES;

EID: 0030064262     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199601150-00026     Document Type: Article

References (35)

1. Bartlett RR, Campion G, Musikic P, Schleyerbach R, Zielinski T, Schlorlemmer H-U. Leflunomide: a novel immunomodulating drug. In: Lewis AJ, Furst DE, eds. Nonsteroidal anti-inflammatory drugs. New York: Marcel Dekker, 1994.
2. Ogawa T, Inazu M, Gotol K, Hayashi S. Effects of leflunomide on glomeronephritis induced by antibasement membrane antibody in rats. Agents Actions 1990; 31: 321.
3. Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol 1985; 7: 7.
4. Giant TT, Fülöp C, Mikecz K, Buzar G, Erhardt P. Immunomodulation of proteoglycan-induced polyarthritis by leflunomide. Int J Immunopharmacol 1992; 23: 105.
5. Hambleton P, McMahon S. Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis. Agents Actions 1990; 29: 328.
6. Pasternak RD, Wadopian NS, Wright RN, Siminoff P, Gylys JA, Buyniski J. Disease modifying activity of HWA486 in rat adjuvant arthritis. Agents Actions 1986; 21: 241.
7. Popovic S, Bartlett RR. Disease modifying activity of HWA486 on the development of SLE in MLR/lpr mice. Agents Actions 1986; 19: 313.
8. Thoenes GH, Sitter T, Langer KH, Bartlett RR, Schleyerbach R. Leflunomide (HWA486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int J Immunopharmacol 1989; 11: 921.
9. Smith-Lang L, Glaser RL, Miller ST, et al. Efficacy of novel immunomodulators leflunomide and rapamycin in autoimmune uveitis. FASEB J 1992; 21: 284.
10. Popovic S, Bartlett RR. The use of murine chronic graft versus rejection (cGvH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agents Actions 1987; 21: 284.
11. McChesney LP, Xiao F, Sankary HN, et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994; 57: 1717.
12. Morris RE, Huang X, Cao W, Zheng B, Shorthouse RA. Leflunomide (HWA486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection and antidonor antibody synthesis in mouse, rat and cynomolgus monkey transplant recipients as well as arterial intimai thickening after balloon catheter injury. Transplant Proc 1995; 27: 430.
13. Küchle CCA, Thoenes GH, Langer KH, Schlorlemmer HU, Bartlett RR, Schleyerbach R. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant Proc 1991; 23: 1083.
14. Williams JW, Xiao F, Foster P, et al. Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994; 57: 1223.
15. Xiao F, Chong AS-F, Foster P, et al. Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation 1994; 58: 826.
16. Morris RE, Huang X, Gregory CR, et al. Studies in experimental models of chronic rejection: use of rapamycin (Sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of grat vascular disease and obliterative bronchiolitis. Transplant Proc 1995; 27: 445.
17. Xiao F, Chong AS-F, Shen J, et al. Pharmacological intervention of chronic transplant rejection. Transplantation (in press).
18. Nair R, Cao W, Morris R. Molecular mechanism of suppression of arterial intimai thickening by lelunomide (LFM): demonstration of direct antiproliferative effect on marine vascular smooth muscle cells (M-VSMC) in vitro and antagonism of action by uridine. J Heart Lung Transplant 1995; (suppl) : 554.
19. Chong AS-F, Finnegan A, Jiang X, et al. Leflunomide, a novel immunosuppressive agent. Transplantation 1993; 55: 1361.
20. Churcher Y, Moss S. E. Modulation of protein tyrosine phosphorylation during G1/S transition in activated human T-lymphoblasts. J Biol Chem 1993; 268: 26144.
21. Cantrell DA, Smith KA. The interleukin-2 T-cell system: a new cell growth model. Science 1984; 224: 1312.
22. Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou T. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes. Transplantation 1991; 51: 232.
23. Chou TC. Derivation and properties of Michaelis-Menton type and Hill type equations for reference ligands. J Theor Biol 1976; 59: 253.
24. Chou TC, Talalay P. Analysis of combined drug effect: a new look at a very old problem. Trends Pharmacol Sci 1983; 4: 450.
25. Morris RE. Immunopharmacology of new xenobiotic immunosuppressive molecules. Semin Nephrol 1992; 12: 304.
26. Zielinski T, Zeitter D, Müllner S, Bartlett RR. Leflunomide, a reversible inhibitor of pyrimidine biosynthesis? Inflammation Res 1995; 44 (suppl): S207.
27. Allison AC, Eugui EM. Inhibitors of de novo purine and pyrimidine synthesis as immunosuppressive drugs. Transplant Proc 1993; 25: 8.
28. Forrest TL, Ware RE, Howard T, Jaffee BD, Denning SM. Novel mechanisms of brequinar sodium immunosuppression on T cell activation. Transplantation 1994; 58: 920.
29. Xu X, Willaims JW, Bremer EG, Finnegan A, Chong AS-F. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995; 280: 12398.
30. Woo J, Kemster B, Tamura K, Starzl TE, Thomson AW. The antilymphocytic activity of brequinar sodium and its potentiation by cytidine. Effects on lymphocyte proliferation and cytokine production. Transplantation 1993; 56: 374.
31. Kahan BD. Toward a rational design of clinical trials of immunosuppressive agents in transplantation. Immunol Rev 1993; 136: 29.
32. Siekiera JJ, Hung SHY, Poe M, Lin CS, Siganl NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989; 341: 755.
33. Harding MW, Galat A, Uehling DE, Schreiber SL. The immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989; 341: 758.
34. Heitman J, Movva NR, Heistand C, Hall MN. FK506-binding protein proline rotamase is a target for the immunosuppressant rapamycin in yeast. Proc Natl Acad Sci USA 1991; 88: 1948.
35. Dumont FJ, Melino MR, Staruch MJ, Koprak SL, Fischer A, Sigal NH. The immunosuppressive macrolides FK and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 1418.